From: Will bevacizumab biosimilars impact the value of systemic therapy in gynecologic cancers?
Clinical indication | Combination regimen | Treatment setting |
---|---|---|
Metastatic colorectal cancer | Intravenous 5-fluorouracil–based chemotherapy | First- or second-line treatment |
Metastatic colorectal cancer | Fluoropyrimidine-irinotecan– or fluoropyrimidine-oxaliplatin–based chemotherapy | Second-line treatment in patients who have progressed on a first-line bevacizumab-containing regimen |
Non-squamous non-small-cell lung cancer | Carboplatin and paclitaxel | First-line treatment of unresectable, locally advanced, recurrent or metastatic disease |
Glioblastoma | Monotherapy | Adult patients with progressive disease following prior therapya |
Metastatic renal cell carcinoma | Interferon alfa | Adult patients |
Cervical cancer | Paclitaxel and cisplatin or paclitaxel and topotecan | Persistent, recurrent or metastatic disease |
Platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer | Paclitaxel, pegylated liposomal doxorubicin or topotecan | Adult patients |
Platinum-sensitive recurrent epithelial ovarian, fallopian tube or primary peritoneal cancerb | Carboplatin and paclitaxel or carboplatin and gemcitabine chemotherapy (followed by bevacizumab) | Adult patients who have relapsed ≥6 months following last treatment with platinum-based chemotherapy |